Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735845

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735845

Global Hyoscine Market Size study, by Type (Hyoscine Butyl Bromide, Hyoscine Hydrobromide), by Mode of Administration (Oral, Patches, Injections) and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

The Global Hyoscine Market is valued at approximately USD 0.41 billion in 2023 and is anticipated to expand at a steady CAGR of 4.80% over the forecast period 2024-2032. Hyoscine, also referred to as scopolamine, is a potent anticholinergic drug extensively employed to prevent and treat motion sickness, nausea, and abdominal cramps caused by gastrointestinal and urological disorders. Its widespread clinical utility, coupled with affordability and a strong safety profile, has contributed to its continued demand across both developed and emerging markets. With a variety of formulations including oral tablets, transdermal patches, and injectable solutions, hyoscine caters to a wide range of therapeutic needs, particularly in travel health, palliative care, and perioperative medicine.

The market's growth trajectory is significantly influenced by the rising global travel activity and increasing awareness of motion sickness management. Moreover, the elderly population, which is particularly susceptible to gastrointestinal disturbances and smooth muscle spasms, contributes meaningfully to the demand for antispasmodic medications like hyoscine. Innovation in drug delivery, such as long-acting patches and controlled-release injectables, has augmented treatment adherence and patient comfort. However, challenges such as drug side effects, including drowsiness and dry mouth, along with availability of alternative therapies, might temper the market's growth to an extent during the assessment period.

In parallel with clinical demand, pharmaceutical companies are proactively expanding their product portfolios through generic launches and patent extensions to bolster market competitiveness. Hyoscine's adaptability in both hospital and retail settings-particularly for its non-invasive patch application-has further pushed its relevance among non-prescription treatments. The trend of shifting toward non-invasive drug delivery and self-administration is giving rise to an increased preference for transdermal patches, particularly in regions with high consumer health awareness. Injections remain crucial in emergency and perioperative settings, ensuring rapid onset of action.

Regionally, North America currently commands a major share of the Global Hyoscine Market, driven by the high prevalence of motion sickness, advanced healthcare infrastructure, and well-established distribution networks. Europe closely follows, benefiting from strong pharmaceutical R&D and heightened awareness of travel-related health conditions. The Asia Pacific region is poised for the most significant growth during the forecast period, propelled by a burgeoning population base, increasing disposable income, and expanding accessibility to healthcare products. Countries such as India, China, and Japan are witnessing higher prescription rates owing to rising gastrointestinal disorders and an expanding generic pharmaceutical industry. Latin America and the Middle East & Africa are gradually progressing, supported by healthcare reforms and a growing retail pharmacy network.

Major market player included in this report are:

  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Baxter International Inc.
  • Alchem International Pvt. Ltd.
  • Novartis AG
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Bayer AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Abbott Laboratories
  • Hikma Pharmaceuticals PLC
  • Zydus Lifesciences Limited

The detailed segments and sub-segment of the market are explained below:

By Type

  • Hyoscine Butyl Bromide
  • Hyoscine Hydrobromide

By Mode of Administration

  • Oral
  • Patches
  • Injections

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Hyoscine Market Executive Summary

  • 1.1. Global Hyoscine Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Type
    • 1.3.2. By Mode of Administration
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Hyoscine Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Hyoscine Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising Prevalence of Motion Sickness and Gastrointestinal Disorders
    • 3.1.2. Growth in Global Travel and Tourism
    • 3.1.3. Expansion of Elderly Population Requiring Antispasmodic Therapy
  • 3.2. Market Challenges
    • 3.2.1. Side-Effect Profile Including Drowsiness and Dry Mouth
    • 3.2.2. Availability of Alternative Antiemetic and Antispasmodic Therapies
    • 3.2.3. Regulatory Constraints on Anticholinergic Use
  • 3.3. Market Opportunities
    • 3.3.1. Innovation in Transdermal Patch and Controlled-Release Formulations
    • 3.3.2. Expansion of Over-the-Counter Distribution Channels
    • 3.3.3. Penetration into Emerging Markets with Growing Healthcare Access

Chapter 4. Global Hyoscine Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunity
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Hyoscine Market Size & Forecasts by Type 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Hyoscine Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 5.2.1. Hyoscine Butyl Bromide
    • 5.2.2. Hyoscine Hydrobromide

Chapter 6. Global Hyoscine Market Size & Forecasts by Mode of Administration 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Hyoscine Market: Mode of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 6.2.1. Oral
    • 6.2.2. Patches
    • 6.2.3. Injections

Chapter 7. Global Hyoscine Market Size & Forecasts by Region 2022-2032

  • 7.1. North America Hyoscine Market
    • 7.1.1. U.S. Hyoscine Market
      • 7.1.1.1. Type breakdown size & forecasts, 2022-2032
      • 7.1.1.2. Mode of Administration breakdown size & forecasts, 2022-2032
    • 7.1.2. Canada Hyoscine Market
  • 7.2. Europe Hyoscine Market
    • 7.2.1. U.K. Hyoscine Market
    • 7.2.2. Germany Hyoscine Market
    • 7.2.3. France Hyoscine Market
    • 7.2.4. Spain Hyoscine Market
    • 7.2.5. Italy Hyoscine Market
    • 7.2.6. Rest of Europe Hyoscine Market
  • 7.3. Asia-Pacific Hyoscine Market
    • 7.3.1. China Hyoscine Market
    • 7.3.2. India Hyoscine Market
    • 7.3.3. Japan Hyoscine Market
    • 7.3.4. Australia Hyoscine Market
    • 7.3.5. South Korea Hyoscine Market
    • 7.3.6. Rest of Asia Pacific Hyoscine Market
  • 7.4. Latin America Hyoscine Market
    • 7.4.1. Brazil Hyoscine Market
    • 7.4.2. Mexico Hyoscine Market
    • 7.4.3. Rest of Latin America Hyoscine Market
  • 7.5. Middle East & Africa Hyoscine Market
    • 7.5.1. Saudi Arabia Hyoscine Market
    • 7.5.2. South Africa Hyoscine Market
    • 7.5.3. Rest of Middle East & Africa Hyoscine Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Boehringer Ingelheim International GmbH
    • 8.1.2. GlaxoSmithKline plc
    • 8.1.3. Baxter International Inc.
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Boehringer Ingelheim International GmbH
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Market Strategies
    • 8.3.2. GlaxoSmithKline plc
    • 8.3.3. Baxter International Inc.
    • 8.3.4. Alchem International Pvt. Ltd.
    • 8.3.5. Novartis AG
    • 8.3.6. Mylan N.V.
    • 8.3.7. Sun Pharmaceutical Industries Ltd.
    • 8.3.8. Pfizer Inc.
    • 8.3.9. Bayer AG
    • 8.3.10. Sanofi S.A.
    • 8.3.11. Teva Pharmaceutical Industries Ltd.
    • 8.3.12. Aurobindo Pharma
    • 8.3.13. Abbott Laboratories
    • 8.3.14. Hikma Pharmaceuticals PLC
    • 8.3.15. Zydus Lifesciences Limited

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!